4569.T Stock - KYORIN Holdings, Inc.
Unlock GoAI Insights for 4569.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $130.09B | $119.53B | $113.27B | $105.53B | $102.90B |
| Gross Profit | $59.51B | $51.41B | $50.17B | $49.44B | $51.63B |
| Gross Margin | 45.7% | 43.0% | 44.3% | 46.8% | 50.2% |
| Operating Income | $12.55B | $6.23B | $5.12B | $5.01B | $5.79B |
| Net Income | $9.09B | $5.47B | $4.72B | $3.93B | $6.13B |
| Net Margin | 7.0% | 4.6% | 4.2% | 3.7% | 6.0% |
| EPS | $158.16 | $92.74 | $82.42 | $68.62 | $106.99 |
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
4569.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | — | — | — | — |
Q4 2025 | Nov 7, 2025 | — | $-10.55 | — | — |
Q3 2025 | Jul 31, 2025 | — | $36.55 | — | — |
Q2 2025 | May 8, 2025 | — | $115.70 | — | — |
Q1 2025 | Feb 4, 2025 | — | $20.61 | — | — |
Q4 2024 | Nov 7, 2024 | — | $6.44 | — | — |
Q3 2024 | Jul 31, 2024 | — | $15.41 | — | — |
Q2 2024 | May 10, 2024 | — | $24.51 | — | — |
Q1 2024 | Feb 6, 2024 | — | $37.55 | — | — |
Q4 2023 | Nov 8, 2023 | — | $18.85 | — | — |
Q3 2023 | Aug 2, 2023 | — | $11.80 | — | — |
Q2 2023 | May 11, 2023 | — | $6.04 | — | — |
Q1 2023 | Feb 6, 2023 | — | $54.71 | — | — |
Q4 2022 | Nov 9, 2022 | — | $1.03 | — | — |
Q3 2022 | Aug 2, 2022 | — | $20.65 | — | — |
Q2 2022 | May 11, 2022 | — | $25.27 | — | — |
Q1 2022 | Feb 4, 2022 | — | $41.24 | — | — |
Q4 2021 | Nov 8, 2021 | — | $10.17 | — | — |
Q3 2021 | Aug 3, 2021 | — | $-8.06 | — | — |
Latest News
Frequently Asked Questions about 4569.T
What is 4569.T's current stock price?
What is the analyst price target for 4569.T?
What sector is KYORIN Holdings, Inc. in?
What is 4569.T's market cap?
Does 4569.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4569.T for comparison